Trials / Unknown
UnknownNCT03449056
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns "de novo" acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied. Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | salbutamol | T2 - T1+1h30: High-nasal flow and salbutamol nebulization |
Timeline
- Start date
- 2019-01-11
- Primary completion
- 2020-01-01
- Completion
- 2020-04-01
- First posted
- 2018-02-28
- Last updated
- 2019-02-12
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03449056. Inclusion in this directory is not an endorsement.